Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment
Abstract Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), which lead to early death due to progressive lung disease. The development of small-molecule modulators that directly interact with CFTR to aid in protein folding (“correctors”) an...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Nature Portfolio
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/ada0900b04f2474491bb981f326adf27 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|